WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Recombine
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
BioSpace | March 27, 2020
CG Oncology, Inc. has announced today an exclusive license, development and commercialization agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") for its oncolytic immunotherapy drug CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China. CG Oncology has completed an investigational Phase 2 study of CG0070 in the United States in patients with BCG-unresponsive, non-muscle-invasive bladder cancer (NMIBC). In addition, CG Oncology is studying th...
Medical
Cytiva, Pall Corporation | June 02, 2021
Danaher Corporation's Life Sciences platform has acquired precision NanoSystems (PNI). PNI is a global leader in technologies and solutions for developing genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher's Life Sciences platform and complement other businesses in the forum, including Cytiva and Pall. "PNI has advanced several exciting innovations, and we're thrilled to welcome this talented team," says Emmanuel Ligner, Danahe...
Xylyx Bio | September 30, 2020
Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Approximately 40% of development costs are associated with preclinical studies, yet 80% of drug candidates fail before reaching Phase I trials, largely due to lack of translatability of efficacy data to hum...
Industrial Impact
MycoWorks | October 19, 2022
Biotechnology company MycoWorks announced today its newest investor GM Ventures, the investment arm of General Motors Co. and their long-term agreement to co-develop Fine Mycelium™ materials for potential use in a range of applications within automotive design. MycoWorks' collaboration with GM marks the exploration of its entry into one of the largest end-use markets for leather and demonstrates the significant opportunity to create more sustainable materials for the automotive space.<...
Research, Medical
Whitepaper
Cell and Gene Therapy, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE